<DOC>
	<DOCNO>NCT00978081</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use drug becomes active expose certain kind light . When drug active , tumor cell kill . PURPOSE : This randomized phase I trial study side effect best dose photodynamic therapy treat patient premalignant early stage head neck tumor .</brief_summary>
	<brief_title>Photodynamic Therapy Treating Patients With Premalignant Early Stage Head Neck Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate toxicity associate aminolevulinic acid-mediated photodynamic therapy administer continuously fractionate dose patient premalignant early stage head neck lesion . Secondary - To assess efficacy regimen patient . OUTLINE : This dose-escalation study photodynamic therapy . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral aminolevulinic acid undergo continuous photodynamic therapy 4-6 hour later . - Arm II : Patients receive aminolevulinic acid arm I undergo fractionated photodynamic therapy 4-6 hour later . After completion study therapy , patient follow 1 month , every 3 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 follow within past 3 month : Erythroplakia dysplasia Severe dysplasia Carcinoma situ head neck standard therapy indicate , accord follow : Medical condition precludes surgery Lesions completely resect base size location Significant functional morbidity would anticipate surgery Refused standard therapy treatment discuss offer No invasive squamous cell carcinoma head neck PATIENT CHARACTERISTICS : ECOG performance status 02 Platelet count ≥ 100,000/mm^3 Total bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 2 time ULN Alkaline phosphatase ≤ 2 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior chronic liver disease cirrhosis liver No porphyria hypersensitivity porphyrins No significant cardiovascular history , opinion cardiologist , would deem patient risk hypotension may occur oral administration aminolevulinic acid ( Levulan® ) No prior adverse reaction ondansetron lorazepam PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>precancerous condition</keyword>
	<keyword>stage 0 hypopharyngeal cancer</keyword>
	<keyword>stage 0 laryngeal cancer</keyword>
	<keyword>stage 0 lip oral cavity cancer</keyword>
	<keyword>stage 0 nasopharyngeal cancer</keyword>
	<keyword>stage 0 oropharyngeal cancer</keyword>
	<keyword>stage 0 paranasal sinus nasal cavity cancer</keyword>
</DOC>